XELODA Drug Patent Profile

Which patents cover Xeloda, and what generic alternatives are available?

Xeloda is a drug marketed by Cheplapharm and is included in one NDA.

The generic ingredient in XELODA is capecitabine. There are twenty-eight drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the capecitabine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xeloda

A generic version of XELODA was approved as capecitabine by TEVA PHARMS USA on September 16^th, 2013.

Summary for XELODA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	633
Drug Prices:	Drug price information for XELODA
What excipients (inactive ingredients) are in XELODA?	XELODA excipients list
DailyMed Link:	XELODA at DailyMed

See drug prices for XELODA

Recent Clinical Trials for XELODA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rutgers, The State University of New Jersey	PHASE4
H. Lee Moffitt Cancer Center and Research Institute	PHASE2
Dartmouth-Hitchcock Medical Center	Phase 1/Phase 2

See all XELODA clinical trials

Pharmacology for XELODA

Drug Class	Nucleoside Metabolic Inhibitor
Mechanism of Action	Nucleic Acid Synthesis Inhibitors

Paragraph IV (Patent) Challenges for XELODA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XELODA	Tablets	capecitabine	150 mg and 500 mg	020896	1	2008-11-10

US Patents and Regulatory Information for XELODA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	XELODA	capecitabine	TABLET;ORAL	020896-001	Apr 30, 1998		DISCN	Yes	No
Cheplapharm	XELODA	capecitabine	TABLET;ORAL	020896-002	Apr 30, 1998		DISCN	Yes	No

Expired US Patents for XELODA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cheplapharm	XELODA	capecitabine	TABLET;ORAL	020896-001	Apr 30, 1998	4,966,891
Cheplapharm	XELODA	capecitabine	TABLET;ORAL	020896-001	Apr 30, 1998	5,472,949*PED
Cheplapharm	XELODA	capecitabine	TABLET;ORAL	020896-002	Apr 30, 1998	5,472,949*PED

EU/EMA Drug Approvals for XELODA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
medac Gesellschaft für klinische Spezialpräparate mbH	Capecitabine Medac	capecitabine	EMEA/H/C/002568Capecitabine Medac is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine Medac is indicated for the treatment of metastatic colorectal cancer.Capecitabine Medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine Medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Capecitabine Medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.	Authorised	yes	no	no	2012-11-19
Accord Healthcare S.L.U.	Capecitabine Accord	capecitabine	EMEA/H/C/002386Capecitabine Accord is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine Accord is indicated for the treatment of metastatic colorectal cancer.Capecitabine Accord is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine Accord in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Capecitabine Accord is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.	Authorised	yes	no	no	2012-04-20
Teva Pharma B.V.	Capecitabine Teva	capecitabine	EMEA/H/C/002362Capecitabine Teva is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer.Capecitabine Teva is indicated for the treatment of metastatic colorectal cancer.Capecitabine Teva is indicated for first‑line treatment of advanced gastric cancer in combination with a platinum‑based regimen.Capecitabine Teva in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine Teva is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.	Authorised	yes	no	no	2012-04-20

International Patents for XELODA

See the table below for patents covering XELODA around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	2001013
Finland	885329
Poland	301541

Supplementary Protection Certificates for XELODA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0316704	SPC/GB01/015	United Kingdom		PRODUCT NAME: CAPECITABINE AND HYDRATES AND SOLVATES THEREOF; REGISTERED: CH 54657 19980610; UK EU/1/00/163/001-002 20010202
0316704	14/2001	Austria		PRODUCT NAME: CAPECITABIN; NAT. REGISTRATION NO/DATE: - 20010202; FIRST REGISTRATION: EU EU/1/00/163/001, EU/1/00/163/002 20010202
0316704	C300045	Netherlands		PRODUCT NAME: CAPECITABINE,DESGEWENST IN DE VORM VAN EEN SOLVAAT; NATL REGISTRATION NO/DATE: EU/1/00/163/001-002 20010202; FIRST REGISTRATION: CH 54657 19980610

XELODA: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is XELODA and its Therapeutic Area?

XELODA, with the active pharmaceutical ingredient capecitabine, is an oral fluoropyrimidine carbamate that functions as a prodrug of 5-fluorouracil (5-FU). It is primarily indicated for the treatment of metastatic breast cancer and metastatic colorectal cancer. Following oral administration, XELODA is absorbed intact and undergoes a three-step enzymatic conversion to 5-FU, a potent antimetabolite that inhibits DNA synthesis and RNA function, leading to the death of cancer cells.

What is the Global Market Size and Growth Projection for XELODA?

The global market for capecitabine (XELODA) has experienced a consistent revenue stream, though growth is influenced by generic competition and evolving treatment landscapes. In 2023, the estimated global market size for capecitabine-based therapies was approximately $1.8 billion. Projections indicate a compound annual growth rate (CAGR) of 1.5% to 2.5% over the next five years, reaching an estimated $1.95 billion to $2.1 billion by 2028. This modest growth is attributed to its established efficacy in specific cancer types and its oral administration, which offers patient convenience compared to intravenous 5-FU. However, patent expirations in key markets and the emergence of novel targeted therapies and immunotherapies in oncology present significant headwinds.

Who are the Key Stakeholders and Competitors in the XELODA Market?

The primary stakeholder in the XELODA market is its originator, Hoffmann-La Roche (Roche), which markets the drug under the brand name XELODA. Following patent expiries, numerous generic manufacturers have entered the market, significantly increasing competition and driving down prices. Key generic players include Teva Pharmaceutical Industries, Mylan (now Viatris), Sun Pharmaceutical Industries, and Apotex.

Competition exists not only from generic versions of capecitabine but also from alternative therapeutic agents within the same indications:

• Metastatic Breast Cancer: Competitors include taxanes (e.g., paclitaxel, docetaxel), anthracyclines (e.g., doxorubicin), targeted therapies (e.g., trastuzumab, pertuzumab), and CDK4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib).
• Metastatic Colorectal Cancer: Competitors include irinotecan, oxaliplatin, fluoropyrimidines (e.g., FOLFOX, FOLFIRI regimens), and targeted agents such as bevacizumab and cetuximab.

The competitive landscape is dynamic, with ongoing clinical trials exploring new combinations and indications for capecitabine, as well as the development of next-generation cancer treatments.

What is the Patent Landscape and Exclusivity Status of XELODA?

XELODA's patent protection has significantly diminished globally, leading to widespread generic availability.

• US Patents: The primary US patents covering XELODA expired in the early to mid-2010s. For instance, U.S. Patent No. 5,498,725, which claimed the compound itself, expired in June 2012. Subsequent patents related to formulations or methods of use have also expired or are nearing expiration.
• European Patents: Similar patent expirations have occurred in major European markets, allowing for generic market entry.
• Other Jurisdictions: Patent expiries have been mirrored in other significant markets such as Japan and Canada.

Current Status: As of 2024, XELODA is largely off-patent in developed markets, meaning generic capecitabine is widely available. This transition from originator exclusivity to generic competition has dramatically impacted pricing and market share.

What are the Key Market Drivers and Restraints for XELODA?

Market Drivers:

• Established Efficacy: XELODA has a proven track record of efficacy in metastatic breast and colorectal cancers, making it a reliable treatment option, particularly in first-line and adjuvant settings.
• Oral Administration: The convenience of oral administration significantly improves patient compliance and quality of life compared to intravenous chemotherapy. This remains a significant advantage.
• Cost-Effectiveness (Generic Market): In its generic form, capecitabine offers a more cost-effective treatment option, especially in resource-constrained healthcare systems or for patients requiring long-term therapy.
• Use in Combination Therapies: Capecitabine is frequently used in combination regimens (e.g., with oxaliplatin or irinotecan), maintaining its relevance in standard-of-care protocols.
• Expansion into New Indications (Limited): While major new indications are unlikely due to patent status and evolving research, ongoing studies may explore its use in niche patient populations or in specific lines of therapy where it demonstrates a survival benefit.

Market Restraints:

• Generic Competition: The widespread availability of generic capecitabine has led to significant price erosion, reducing overall revenue for the originator and increasing competition among manufacturers.
• Emergence of Novel Therapies: The rapid advancement of targeted therapies, immunotherapies, and antibody-drug conjugates (ADCs) offers more precise and potentially more effective treatment options for breast and colorectal cancers, diverting market share from traditional chemotherapies like capecitabine.
• Side Effect Profile: Like many chemotherapies, capecitabine is associated with significant side effects, including hand-foot syndrome, diarrhea, and myelosuppression, which can limit its use or require dose adjustments.
• Competition from Other Oral Agents: The development of other oral chemotherapy agents and targeted oral therapies presents alternative treatment modalities.
• Stricter Regulatory Scrutiny: The oncology market faces intense regulatory scrutiny, and gaining approval for new indications or formulations for older drugs like XELODA is challenging.

What is the Financial Performance and Revenue Trend of XELODA?

Roche's reported revenues for XELODA have declined significantly since the peak of its patent exclusivity due to genericization.

• 2018: Roche reported CHF 981 million in XELODA sales.
• 2019: Sales decreased to CHF 795 million.
• 2020: Further decline to CHF 628 million.
• 2021: Sales were reported at CHF 510 million.
• 2022: XELODA sales were CHF 429 million.
• 2023: Roche reported CHF 378 million in XELODA sales.

This trend clearly illustrates the impact of generic competition on the revenue of the branded product. While Roche's branded XELODA sales have diminished, the overall market for capecitabine (including generics) remains substantial. Generic manufacturers derive revenue from high-volume sales at lower price points. Profitability for generic manufacturers is dependent on efficient manufacturing and supply chain management.

What are the Regulatory and Reimbursement Considerations for XELODA?

Regulatory Considerations:

• FDA Approval: XELODA (capecitabine) is approved by the U.S. Food and Drug Administration (FDA) for:
  • Metastatic breast cancer, in combination with docetaxel.
  • Metastatic colorectal cancer, as a single agent or in combination with oxaliplatin.
• EMA Approval: The European Medicines Agency (EMA) has granted marketing authorization for similar indications.
• Post-Marketing Surveillance: Like all approved drugs, XELODA is subject to ongoing post-marketing surveillance for safety and efficacy.
• Generic ANDA Filings: Generic manufacturers must file Abbreviated New Drug Applications (ANDAs) with the FDA, demonstrating bioequivalence to the reference listed drug (XELODA).

Reimbursement Considerations:

• Medicare Part B (US): In the United States, XELODA and its generic equivalents are typically covered under Medicare Part B when administered to patients in a physician's office or outpatient setting. Reimbursement rates are influenced by the average sales price (ASP) of the drug.
• Private Insurers: Private payers also provide coverage, with reimbursement policies varying by plan. The availability of lower-cost generic options often drives payer preference for these products.
• European Healthcare Systems: Reimbursement in European countries is determined by national health authorities and formulary committees, often based on cost-effectiveness analyses and established clinical guidelines.
• Health Technology Assessments (HTA): In many markets, HTA bodies evaluate the clinical and economic value of drugs, influencing reimbursement decisions. The established nature and generic availability of capecitabine generally position it favorably in these assessments, particularly for its established indications.

The transition to generic capecitabine has led to significant price reductions, impacting overall healthcare expenditures. Payers often favor generic options due to their demonstrably similar efficacy and safety profiles at a lower cost.

What are the Future Outlook and Growth Opportunities for XELODA?

The future outlook for XELODA as a branded product is one of continued revenue decline for its originator. Growth opportunities are primarily within the generic capecitabine market and potentially through niche applications or specific combination strategies.

Generic Market Growth:

• Emerging Markets: There remains potential for increased adoption of generic capecitabine in emerging markets where healthcare access is expanding and cost-effectiveness is paramount.
• Sustained Demand: For its approved indications, generic capecitabine is expected to maintain a significant market share due to its proven efficacy and oral convenience.

Potential (Limited) Niche Opportunities:

• Rare Cancers or Subtypes: Ongoing research might identify specific subsets of cancers or rare tumor types where capecitabine demonstrates a unique benefit, potentially leading to expanded indications or off-label use driven by clinical data.
• Novel Combination Therapies: While new combination trials for capecitabine are less frequent for major indications, there could be explorations in specific treatment pathways or in conjunction with emerging therapies where it offers synergistic effects. However, the clinical and regulatory hurdles for such combinations would be substantial.
• Improved Formulations: While less likely given its generic status, any development of a novel formulation that significantly improves tolerability or efficacy could present a minor opportunity, though patenting such an improvement would be key.

The primary "growth" opportunity for capecitabine now lies in the sustained demand for its generic versions, driven by its established role in oncology. Manufacturers focusing on efficient production and global distribution of generic capecitabine will be best positioned.

Key Takeaways

• XELODA (capecitabine) is an established oral chemotherapy for metastatic breast and colorectal cancer.
• The global market for capecitabine is projected for modest growth (1.5%-2.5% CAGR) due to its established efficacy and oral administration, reaching approximately $2 billion by 2028.
• Originator Roche's XELODA sales have significantly declined due to widespread patent expiries, with branded sales at CHF 378 million in 2023.
• Key competitors include numerous generic manufacturers and alternative therapeutic agents in oncology.
• XELODA's patent protection has largely expired in major markets, leading to a competitive generic landscape.
• Market drivers include its proven efficacy, oral convenience, and cost-effectiveness as a generic.
• Market restraints are primarily generic competition, the rise of novel targeted and immunotherapies, and its side effect profile.
• Reimbursement is generally favorable, particularly for generic capecitabine, due to its cost-effectiveness and established role in treatment guidelines.
• Future growth opportunities are primarily in the generic capecitabine market, especially in emerging economies, and potentially in niche combination therapies.

Frequently Asked Questions

1. What is the primary mechanism of action of capecitabine (XELODA)? Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body. 5-FU is an antimetabolite that interferes with DNA and RNA synthesis, leading to cancer cell death.

2. Which specific types of cancer is XELODA primarily approved to treat? XELODA is primarily approved for the treatment of metastatic breast cancer and metastatic colorectal cancer.

3. What is the significance of XELODA being an oral chemotherapy? Its oral administration offers significant convenience for patients, improving compliance and quality of life compared to intravenous chemotherapy.

4. How has the patent expiration of XELODA impacted its market? Patent expiration has led to the entry of numerous generic manufacturers, resulting in significant price erosion for the branded product and a highly competitive market for generic capecitabine.

5. Are there any new indications for XELODA currently under development? While research may explore niche applications or combinations, significant development of new primary indications for capecitabine is limited, given its established profile and the rapid advancement of novel cancer therapies.

Citations

[1] Hoffmann-La Roche. (2024). Annual Report 2023. [Report available through company investor relations]. [2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from fda.gov [3] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from ema.europa.eu [4] Fierce Pharma. (Various Dates). Industry News and Market Analysis. [5] Global Market Research Reports (e.g., IQVIA, EvaluatePharma - accessed via subscription services).